News in the Life Sciences Industry

SHANGHAI, Aug. 9, 2018 /PRNewswire/ -- In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103 (TG103) injection: an innovative, humanized, long-acting recombinant glucagon-like peptide-1 (hGLP-1) fused... Read more ››

BEIJING, China and CAMBRIDGE, Mass., Aug. 9, 2018 /PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology... Read more ››

SUZHOU, China, Aug. 6, 2018 /PRNewswire/ -- Cure Genetics Co., Ltd ("CureGenetics"), a biotechnology company dedicated to the development of life-saving transformative medicines and molecular diagnostics using best-in-class gene editing technologies, announced the closing of $17 million Series... Read more ››

-- 2Q18 Total Sales Up 25.5% YoY and Non-GAAP Adjusted Net Income Down 2.8% YoY in RMB terms, or
Total Sales Up 34.8% YoY to $120.4 Million and Net Income Down 7.7% YoY to $28.6 Million in USD terms --
-- 1H18 Total Sales Up 19.5% YoY and Non-GAAP Adjusted Net Income Down 0.4%... Read more ››

LENOIR CITY, Tenn., Aug. 1, 2018 /PRNewswire/ -- Thanks to Janus Global Operations' explosive ordnance experts in Ramadi, Iraq, ISIS's efforts to disrupt stabilization and deny cancer treatment to Iraqi patients have failed. Janus Global personnel cleared a safe path through a building laden... Read more ››

SILVER SPRING, Md., Aug. 1, 2018 /PRNewswire/ -- On Aug. 3, the U.S. Food and Drug Administration will be hosting a public advisory committee meeting to review data from the most recent assessment of the... Read more ››

BEIJING, July 31, 2018 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading cancer hospital operations management solutions provider and operator of a network of radiotherapy and diagnostic imaging centers in China, today announced... Read more ››

WUXI, China, July 30, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biotechnology platform company, offering end-to-end solutions for discovery, development and manufacturing, today announced that a process validation campaign at the 6,000L scale has been... Read more ››